Main Menu

NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Celyad Oncology SA (F: 1C0)

 
1C0 Technical Analysis
4
As on 10th Nov 2025 1C0 STOCK Price closed @ 0.25 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.38 & Sell for SHORT-TERM with Stoploss of 0.25 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

1C0STOCK Price

Open 0.16 Change Price %
High 0.25 1 Day 0.07 38.89
Low 0.16 1 Week 0.08 47.06
Close 0.25 1 Month -0.02 -7.41
Volume 3966 1 Year -0.03 -10.71
52 Week High 1.21 | 52 Week Low 0.16
 
F Germany Most Active Stocks
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
ENB 47.60 -0.92%
TEF 3.84 -0.52%
TEF 3.84 -0.52%
WHL 5150.00 -0.44%
WDI 0.05 -37.50%
 
F Germany Top Gainers Stocks
JYR 1000000.00 10000000000.00%
JYR 1000000.00 10000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
NT5 1000000.00 4629529.50%
NT5 1000000.00 4629529.50%
NT5 1000000.00 4629529.50%
0AI 11.30 14025.00%
 
F Germany Top Losers Stocks
TUUF 0.00 -100.00%
TUUF 0.00 -100.00%
TUUF 0.00 -100.00%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
 
 
1C0
Daily Charts		 1C0
Intraday Charts		 Whats New @
Bazaartrend		 1C0
Free Analysis
 
1C0 Important Levels Intraday
RESISTANCE0.42
RESISTANCE0.37
RESISTANCE0.33
RESISTANCE0.30
SUPPORT0.20
SUPPORT0.17
SUPPORT0.13
SUPPORT0.08
 
1C0 Forecast November 2025
Share
4th UP Forecast0.35
3rd UP Forecast0.32
2nd UP Forecast0.3
1st UP Forecast0.28
1st DOWN Forecast0.22
2nd DOWN Forecast0.2
3rd DOWN Forecast0.18
4th DOWN Forecast0.15
 
1C0 Weekly Forecast
4th UP Forecast0.31
3rd UP Forecast0.29
2nd UP Forecast0.28
1st UP Forecast0.27
1st DOWN Forecast0.23
2nd DOWN Forecast0.22
3rd DOWN Forecast0.21
4th DOWN Forecast0.19
 
1C0 Forecast2025
4th UP Forecast2.27
3rd UP Forecast1.62
2nd UP Forecast1.22
1st UP Forecast0.82
1st DOWN Forecast-0.32
2nd DOWN Forecast-0.72
3rd DOWN Forecast-1.12
4th DOWN Forecast-1.77
 
Celyad Oncology SA ( F Germany Symbol : 1C0 )
Sector : N/A And Other Stocks in Same Sector
 
1C0 Other Details
Segment EQ
Market Capital 43674880.00
Sector
Industry
Offical website >
 
1C0 Address
1C0
 
1C0 Latest News
 
Your Comments and Response on Celyad Oncology SA
 
1C0 Business Profile
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T therapy that is in Phase 1 clinical trial for the treatment of hematological malignancies and solid tumors. The company's preclinical candidates, include allogeneic CAR-T candidate for the treatment of solid tumors; CYAD-221, shRNA based allogeneic CAR-T candidate to treat B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting natural killer group 2D ligands (NKG2D) and an undisclosed membrane protein. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. Address: Axis Business Park, Mont-Saint-Guibert, Belgium, 1435
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service